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Background: One of the problems associated with osteosarcoma is the frequent formation of micrometastases in
the lung prior to diagnosis because the development of metastatic lesions often causes a fatal outcome. Therefore,
the prevention of pulmonary metastases during the early stage of tumor development is critical for the
improvement of the prognosis of osteosarcoma patients. In Japan, soy is consumed in a wide variety of forms, such
as miso soup and soy sauce. The purpose of this study is to investigate the effect of genistein, an isoflavone found
in soy, on the invasive and motile potential of osteosarcoma cells.
Methods: LM8 cells were treated for 3 days with various concentrations of genistein. The effect of genistein on cell
proliferation was determined by DNA measurement in the cultures and 5-bromo-2’-deoxyuridine (BrdU)
incorporation study. The assays of cell invasion and motility were performed using the cell culture inserts with
either matrigel-coated membranes or uncoated membranes in the invasion chambers. The expression and
secretion of MMP-2 were determined by immunohistochemistry and gelatin zymography. The subcellular
localization and cellular level of β-catenin were determined by immunofluorescence and Western blot. For
examining cell morphology, the ethanol-fixed cells were stained with hematoxylin-eosin (H&E). The expression
of osteocalcin mRNA was determined by reverse transcription-polymerase chain reaction (RT-PCR).
Results: Genistein dose-dependently inhibits cell proliferation. Genistein-treated cells were less invasive and less
motile than untreated cells. The expression and secretion of MMP-2 were lower in the genistein-treated cultures
than in the untreated cultures. β-Catenin in untreated cells was located in the cytoplasm and/or nucleus, while in
genistein-treated cells it was translocated near to the plasma membrane. The level of β-catenin was higher in
genistein-treated cells than in untreated cells. Treatment of LM8 cells with genistein induced morphological
changes, markedly decreased the formation of multilayer masses of cells, and markedly increased the expression of
osteocalcin mRNA.
Conclusions: Genistein decreased invasive and motile potential by inducing cell differentiation in LM8 cells.
Genistein may be useful as an anti-metastatic drug for osteosarcoma through its differentiation-inducing effects.
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Osteosarcoma occurs mainly in the metaphyseal region
of the long bones of young people. The most common
sites affected are the distal femur, the proximal tibia and
the proximal humerus [1,2]. Osteosarcoma grows ag-
gressively at the primary site and often develops micro-
metastases in the lung prior to diagnosis. The primary
treatment of osteosarcoma is the complete removal of
tumor by wide excision and aggressive adjuvant chemo-
therapy [3]. Despite progress in chemotherapy, the de-
velopment of metastatic tumors in the lung often has a
fatal outcome [2,4,5]. Therefore, the prevention of
pulmonary metastases during the early stage of tumor
development is critical for the improvement of the
prognosis of osteosarcoma patients.Figure 1 Effect of genistein on cell proliferation and DNA replication.
DNA content of the cultures was measured. *p < 0.01 (compared with the
(open circle) or with (filled circle) 50 μM genistein, the DNA content of the
with the values for the untreated cultures). (C) LM8 cells were treated for
and immunofluorescence staining of BrdU incorporated into DNA was p
bar: 50 μm. (D) LM8 cells were treated for 3 days without (left panel) or
Scale bar: 50 μm.Metastasis is composed of multiple sequential steps,
including cell detachment from the primary tumor, cell
motility and invasion, angiogenesis, intravasation into
blood, and extravasation into distant organs. A number
of factors, such as MMP-2 and vascular endothelial
growth factor (VEGF) [6-10], are involved in tumor
growth, invasion, and metastasis. An LM8 osteosarcoma
cell line with high metastatic potential to the lung was
established from murine Dunn osteosarcoma cells,
which did not develop pulmonary metastasis when
implanted subcutaneously (s.c.) into the backs of C3H
mice [6]. LM8 cells have been used as an excellent tool
for studying inhibitory agents against pulmonary metas-
tasis [7,8]. Previously, we reported that treatment of
nude mice implanted s.c. with LM8 cells into the backs(A) LM8 cells were treated for 3 days with 0–50 μM genistein, and the
values for the untreated cultures). (B) LM8 cells were treated without
cultures was measured at the indicated intervals. *p < 0.01 (compared
3 days without (left panel) or with (right panel) 50 μM genistein,
erformed. Both set of images are of the same field of view. Scale
with (right panel) 50 μM genistein and stained with trypan blue.
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ceptor-γ (PPARγ) ligand, decreased the expression of
MMP-2 and VEGF within the primary tumor and inhib-
ited the development of pulmonary metastasis [8].
Soy contains phytoestrogen isoflavones (e.g. genistein,
daidzein). In Japan, soy is widely consumed in a wide
variety of forms, such as non-fermented foods (dried
and green soybeans, tofu, soy milk) and fermented foods
(miso, soy sauce). An epidemiological study has shown
that consumption of miso soup is inversely associated
with the risk of breast cancer [11]. Several experimental
studies have shown that genistein inhibits the growth of
tumors [12-14]. In the present study, we performed
in vitro experiments to analyze the effect of genistein on
the growth, invasion, and motility of LM8 cells. Since β-
catenin is associated with tumor cell growth, invasion,
motility, and metastasis [15-17], the effect of genistein
on the cellular level and subcellular localization of β-
catenin was also examined.Figure 2 Effect of genistein on subcellular localization and
cellular level of β-catenin. (A) LM8 cells were treated for 3 days
without (left panel) or with (right panel) 50 μM genistein, and
immunofluorescence staining of β-catenin was performed. Scale bar:
50 μm. (B) LM8 cells were treated for 3 days without or with 50 μM
genistein, and the expression of β-catenin and actin was analyzed
by Western blot.Results
Effect of genistein on cell proliferation and DNA
replication
We first evaluated the anti-proliferative effect of genis-
tein against LM8 cells. For this, LM8 cells were treated
for 3 days with genistein at the indicated concentrations
and the DNA content of the cultures was measured. The
untreated cultures (i.e., genistein was absent during the
3-day treatment period) contained 23.9 μg/35-mm plate
of DNA. Genistein dose-dependently decreased the
DNA content of the cultures (Figure 1A). Genistein at
50 μM decreased the DNA content by 91%. Figure 1B
shows the time course of the genistein-induced changes
in the DNA content. In the untreated and genistein-
treated cultures, the DNA content increased during the
3-day treatment period. On day 1, there was no differ-
ence in the DNA content between the two cultures. On
days 2 and 3, the DNA content of the genistein-treated
cultures was significantly lower than that of the un-
treated cultures.
LM8 cells were incubated with 5-bromo-2’-deoxyuridine
(BrdU) during the last 90 min of the 3-day treatment
period to label DNA synthesis (Figure 1C). In the un-
treated and genistein-treated cultures, positive BrdU im-
munofluorescence staining was observed in the nucleus.
The BrdU-labeling index of the genistein-treated cul-
tures (32.4 ± 3.8%) was significantly (p < 0.01) lower than
that of the untreated cultures (56.4 ± 3.0%).
To examine the effect of genistein on cell viability, the
trypan blue exclusion test was performed (Figure 1D). In
the untreated and genistein-treated cultures, cells that
attached to the bottom of the plates excluded trypan
blue.Effect of genistein on subcellular localization and cellular
level of β-catenin
The subcellular localization of β-catenin was examined by
immunofluorescence. In the untreated cultures, positive
β-catenin immunofluorescence staining was observed in
the cytoplasm and/or nucleus and was not observed at
the plasma membrane (Figure 2A, left panel). In the
genistein-treated cultures, positive β-catenin immuno-
fluorescence staining shifted in localization near to the
plasma membrane and was not observed in the nucleus
(Figure 2A, right panel).
The cellular level of β-catenin was examined by West-
ern blot. The intensity of the band corresponding to β-
catenin was stronger in the genistein-treated cultures
than in the untreated cultures (Figure 2B), indicating
that genistein increased the cellular level of β-catenin.
Effect of genistein on invasion, motility, MMP-2, and
alkaline phosphatase (ALP)
LM8 cells, which had been treated for 3 days without or
with 50 μM genistein, were harvested by trypsinization,
and cell invasion and cell motility assays were per-
formed. When experiments were performed using
matrigel-coated membranes, the absorbance of the dye
extracted from genistein-treated cells was 24% of that
extracted from untreated cells (Figure 3A). This indi-
cates that genistein-treated cells were less invasive than
untreated cells. When experiments were performed
using uncoated membranes, the absorbance of the dye
extracted from genistein-treated cells was 40% of that
Figure 3 Effect of genistein on invasion, motility, MMP-2, and ALP. (A and B) LM8 cells were treated for 3 days without or with 50 μM
genistein and harvested by trypsinization. Cell invasion and motility assays were performed using either matrigel-coated membranes (A) or
uncoated membranes (B). *p < 0.01 (compared with the values for untreated cells). (C) LM8 cells were treated for 3 days without (left panel) or
with (right panel) 50 μM genistein, and immunohistochemical staining of MMP-2 was performed. Scale bar: 50 μm. (D) LM8 cells were treated for
3 days without or with 50 μM genistein. The activity of MMP-2 secreted into conditioned media during the last 24 h of the 3-day treatment was
assayed by gelatin zymography. Arrowhead shows the preform of MMP-2. (E) LM8 cells were treated for 2 days without or with 50 μM genistein,
and cellular ALP activity was measured. *p < 0.01 (compared with the values for untreated cells).
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that genistein-treated cells were less motile than un-
treated cells.
Since MMP-2 degrades type IV collagen, which is
present in vascular and subepithelial basement mem-
branes, and plays a pivotal role in cell invasion [9], the
expression of MMP-2 was examined by immunohisto-
chemical staining (Figure 3C). In both untreated and
genistein-treated cells, positive MMP-2 immunostaining
was observed in the cytoplasm. The intensity of immu-
nostaining was weaker in genistein-treated cells than in
untreated cells, thus indicating that genistein-treated
cells expressed less MMP-2 than untreated cells.
The activity of MMP-2 secreted into conditioned media
during the last 24 h of the 3-day treatment period was
assayed by gelatin zymography (Figure 3D). MMP-2 was
secreted from both untreated and genistein-treated cells;
however, the activity of MMP-2 secreted from genistein-
treated cells was lower than that secreted from untreated
cells. Low MMP-9 activity was detected in conditioned
media from untreated cells, but not genistein-treated cells.The ALP activity in LM8 cells is higher than that in
Dunn cells [6], suggesting that the ALP activity in osteo-
sarcoma cells may be associated with metastatic potential.
We treated LM8 cells without or with 50 μM genistein for
2 days and measured cellular ALP activity (Figure 3E).
The ALP activity in genistein-treated cells (7.9 ± 0.2 nmol/
min/μg DNA) was significantly lower than that in un-
treated cells (16.9 ± 1.5 nmol/min/μg DNA).
Does genistein induce the differentiation of LM8 cells?
We stained ethanol-fixed LM8 cells with hematoxylin-
eosin (H&E) and observed cell morphology. In the un-
treated cultures, the majority of cells (92.0 ± 2.0%) were
cuboidal in shape with filopodial and lamellipodial struc-
tures surrounding the cell surface (Figure 4A, left panel).
These cells grew to form numerous multilayer masses
even at low cell density (in ellipse in Figure 4A). The
genistein-treated cultures contained two morphologically
different cell types; one was cuboidal in shape and the
other was spindle-shaped, which became more flattened
with clear cell-cell margins (Figure 4A, right panel). The
Figure 4 Effect of genistein on differentiation of LM8 cells.
(A) LM8 cells were treated for 3 days without (left panel) or with
(right panel) 50 μM genistein, fixed with ethanol, and stained with
H&E. Scale bar: 50 μm. (B) LM8 cells were treated for 3 days without
or with 50 μM genistein, and the expression of mRNAs of
osteocalcin, Drg-1, and β-actin was examined by RT-PCR. (C) LM8
cells were treated for 3 days without (left panel) or with (right panel)
50 μM genistein, and immunohistochemical staining of Drg-1 was
performed. Scale bar: 50 μm.
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number of cells was 46.4 ± 2.9%. Multilayered cells were
markedly decreased in the genistein-treated cultures.
These findings suggest that genistein may induce the dif-
ferentiation of LM8 cells.
To confirm this, we examined the expression of mRNAs
of osteocalcin, which is a marker of mature osteoblasts
[18], and differentiation-related gene-1 (Drg-1), which is
associated with the induction of differentiation in tumors
[19], by reverse transcription-polymerase chain reaction
(RT-PCR) (Figure 4B). Untreated cells expressed a low
level of osteocalcin mRNA, while genistein-treated cells
expressed a markedly high level of osteocalcin mRNA.
Untreated cells expressed a significant level of Drg-1
mRNA. The level of Drg-1 mRNA in genistein-treated
cells was similar to that in untreated cells.The subcellular localization of Drg-1 was examined by
immunohistochemical staining. In untreated cells, posi-
tive Drg-1 immunostaining was observed in the cyto-
plasm (Figure 4C, left panel), while in genistein-treated
cells, it was mostly observed in the nucleus (Figure 4C,
right panel).
Discussion
Since genistein has been reported to inhibit tumor
growth [12-14], we first examined the effect of genistein
on the proliferation of LM8 cells. The results of BrdU
incorporation into DNA and DNA measurement
revealed that genistein inhibited DNA replication and
cell proliferation in cultures of LM8 cells (Figure 1A and
1C). Of course, there is concern that this inhibition
could be due to a cytotoxic effect of genistein on LM8
cells. However, this does not appear to be the case be-
cause cells did not detach from the bottom of the plates
during the 3-day treatment period. Moreover, the results
of the trypan blue exclusion test showed that genistein-
treated cells that attached to the bottom of the plates
were viable cells (Figure 1D). Genistein at a higher con-
centration (100 μM) also inhibited the proliferation of
LM8 cells without affecting cell viability (data not
shown). These findings indicate that genistein-induced
inhibition of cell proliferation was not due to a cytotoxic
effect. There are reports on the effect of genistein on the
proliferation of normal cells. In cultures of 3T3-L1 fibro-
blasts, genistein at 50 and 100 μM inhibits cell prolifera-
tion [20]. In cultures of endothelial cells, genistein at
lower concentrations (0.001-10 nM) stimulates cell pro-
liferation, while at a higher concentration (1 μM) this
chemical inhibits it [21].
When LM8 cells are implanted s.c. into the backs of
mice, a 100% pulmonary metastatic rate is observed
within 4 weeks [6-8]. The initial step of metastasis is cell
detachment from the primary tumor. Since β-catenin
is essential for cadherin-mediated cell-cell adhesion,
reduced expression of β-catenin and cadherins at the cell
surface is associated with tumor metastasis [22,23]. Loss
of membranous β-catenin occurs commonly in primary
colorectal cancers with metastatic potential and in the
corresponding colorectal liver metastases [23]. Our
results of immunofluorescence showed loss of mem-
branous β-catenin in LM8 cells (Figure 2A, left panel),
indicating that cell-cell adhesiveness may be reduced in
LM8 cells.
Genistein affects the subcellular localization and ex-
pression level of β-catenin in normal cells. For example,
treatment of mouse HC11 mammary epithelial cells with
genistein increases membranous β-catenin [24]. In mam-
mary glands of young female rats fed a genistein-
containing diet, β-catenin is predominantly localized to
ductal epithelial cell membranes [25] and the level of
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diet [24]. Therefore, we examined whether genistein
affects the subcellular localization and cellular level of
β-catenin in LM8 cells. In genistein-treated cells, im-
munofluorescence staining of β-catenin was observed
near the plasma membrane (Figure 2A, right panel).
The results of Western blot showed that genistein-
treated cells contained higher levels of β-catenin than
untreated cells (Figure 2B). These findings suggest that
genistein may promote intracellular adhesion of LM8
cells. This is the first report to focus on the subcellu-
lar localization and cellular level of β-catenin following
genistein treatment in osteosarcoma cells.
The next step of metastasis is invasion of tumor cells
into basement membranes, which involves distinct
events, such as cell motility and MMP expression. Inva-
sive tumors exhibit active migration and high levels of
MMPs [9]. LM8 cells have been reported to exhibit
higher invasive potential, higher MMP-2 activity, and
higher ALP activity than Dunn cells with no metastatic
potential [6]. In patients with osteosarcoma, high levels
of ALP activity in serum are associated with a poor clin-
ical outcome [3]. In the present study, we found that
genistein-treated cells were less invasive and less motile
(Figure 3A and 3B), exhibited lower expression and se-
cretion of MMP-2 (Figure 3C and 3D), and exhibited
lower ALP activity (Figure 3E) compared with untreated
cells. Taken together, our findings suggest that genistein-
treated cells might lose metastatic potential.
When β-catenin is translocated to the nucleus, it acti-
vates target genes, such as cyclin D1 and c-myc, and
promotes the growth of tumor cells [15,26,27]. In
intestinal-type gastric cancer, β-catenin in the nucleus
not only plays a role in early tumor growth, but it also
functions in initiation of invasive processes [27]. In
osteosarcoma that has metastasized to the lung, β-
catenin is detected in the cytoplasm and/or nucleus,
whereas in primary osteosarcoma that has not metasta-
sized for more than five years, it is not detected in the
cytoplasm and/or nucleus [16], indicating that the pres-
ence of β-catenin in the cytoplasm and/or nucleus is a
marker of metastatic potential of osteosarcoma to the
lung. Our results of immunofluorescence showed that
β-catenin was present in the cytoplasm and/or nucleus
of LM8 cells (Figure 2A, left panel) and that after treat-
ment of LM8 cells with genistein, β-catenin was trans-
located near to the plasma membrane and was not
found in the nucleus (Figure 2A, right panel). This
translocation of β-catenin may result in decreases in
proliferative rate and invasive potential of genistein-
treated cells. A similar translocation of β-catenin from
the nucleus to the plasma membrane has been reported
in human HT-29 colon cancer cells treated with thiazo-
lidinedione, a PPARγ ligand [17].Treatment of LM8 cells with genistein induced mor-
phological changes (Figure 4A) and markedly increased
the level of osteocalcin mRNA (Figure 4B). Moreover,
this treatment markedly decreased the formation of
multilayer masses (Figure 4A), suggesting that genistein-
treated cells grew with contact inhibition. Contact inhib-
ition is a characteristic of normal cells grown on plastic
culture plates, which is lost in cancerous cells [28]. On
the basis of these findings, we concluded that genistein
induced the differentiation of LM8 cells. There are a few
reports on the association of genistein with cell differen-
tiation. Treatment of mouse B16 melanoma cells with
genistein induces morphological changes characteristic
of differentiation, such as enlargement of the soma and
nuclei together with the formation of dendritic-like
structures [12]. Treatment of human MG 63 osteosar-
coma osteoblasts with genistein increases the level of
collagen and stimulates the formation of calcification
foci [13].
Drg-1 is expressed at lower levels in tumors than
in normal tissue [19,29]. Overexpression of Drg-1
gene in human SW620 metastatic colon cancer cells
induces morphological changes that are similar to
differentiation-specific changes induced by known dif-
ferentiation reagents such as tributyrin and a ligand of
retinoid X receptor LG268 [30], thus indicating that
Drg-1 plays a role in differentiation of tumor cells.
However, there is a contradictory report on the in-
volvement of Drg-1 in cell differentiation. Human
hepatocellular carcinomas express a higher level of
Drg-1 than non-tumor liver or cirrhotic and benign
liver lesions [31]. Moreover, hepatocellular carcinomas
that are moderately and poorly differentiated express a
higher level of Drg-1 than those that are well differen-
tiated [31]. The positive or negative association of Drg-
1 with cell differentiation depends on tumor types.
Therefore, we examined the effect of genistein on the
expression of Drg-1 mRNA by RT-PCR. LM8 cells sig-
nificantly expressed Drg-1 mRNA. Genistein did not
increase the expression of Drg-1 mRNA in LM8 cells
(Figure 4B). Thus, the expression of Drg-1 in LM8 cells
appears not to be associated with the induction of cell
differentiation.
Drg-1 is located in the cytoplasm of human EJ bladder
carcinoma cells [29], human hepatocellular carcinoma
cells [31], and human prostate cancer cells [32]. Our
results of immunohistochemical staining also reveal that
Drg-1 in LM8 cells was located in the cytoplasm
(Figure 4C, left panel). After treatment of LM8 cells with
genistein, Drg-1 mostly shifted in localization from the
cytoplasm to the nucleus (Figure 4C, right panel). A
study with human U2OS osteosarcoma cells expressing
Drg-1 small interfering RNA showed that Drg-1 is asso-
ciated with the production of osteocalcin [33]. Taken
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of genistein-treated cells may play a role in the expres-
sion of osteocalcin mRNA.
In postmenopausal Japanese women [11] and Asian-
American women [34], the risk of breast cancer is in-
versely associated with isoflavone intake during adult
life. Asian-American women who are high consumers of
isoflavone (>12.68 mg/1,000 kcal) show a significantly
reduced risk of breast cancer compared with those who
are low consumers (≤1.79 mg/1,000 kcal) [34]. However,
isoflavones at the levels commonly consumed by non-
Asian US women (an average intake equivalent to less
than one serving of tofu per week) have little effect on
breast cancer risk [35]. In mice implanted with human
253J B-V bladder cancer cells, dietary genistin (0.14% of
the diet), the natural form of genistein in soy, inhibits
tumor growth at the primary site and pulmonary metas-
tasis [14]. In mice implanted with human PC3-M pros-
tate cancer cells, dietary genistein (100 and 250 mg/kg
diet) inhibits pulmonary metastasis without affecting
tumor growth at the primary site [36].
Conclusions
Genistein induced cell differentiation and translocated
β-catenin near to the plasma membrane, resulting in
lowering of the proliferative rate and invasive potential of
LM8 cells. Genistein may be useful as an anti-metastatic




Genistein (Sigma-Aldrich, St. Louis, MO) was dissolved
in dimethyl sulfoxide. LM8 cells (RBRC-RCB1450; Riken
BRC Cell Bank, Ibaraki, Japan) at a concentration of
1.25 × 103 cells/cm2 were seeded on a 35 mm plate in the
culture medium, which contained 10% fetal bovine serum
(FBS), 100 units/ml penicillin, and 100 μg/ml strepto-
mycin in Dulbecco’s modified Eagle’s medium (DMEM).
After 24 h of seeding, the medium was replaced with cul-
ture medium containing genistein at the indicated con-
centrations. Then, cells were incubated for 1–3 days.
For trypan blue exclusion test, cells were treated for
3 days without or with 50 μM genistein, washed twice
with phosphate-buffered saline (PBS), stained for 1 min
with 0.25% trypan blue in PBS, and washed 3 times with
PBS for phase-contrast microscopy analysis (magnifica-
tion: ×100).
Measurements of DNA and ALP activity
For DNA measurement, cells were treated for 1–3 days
without or with genistein (10–50 μM), harvested in
0.3 ml of solution A (10 mM Tris, 0.1% Triton X-100,
pH 7.5), sonicated briefly at 0°C, and centrifuged. DNAin the supernatant was measured fluorometrically by the
method of Hinegardner [37] using calf thymus DNA as a
standard. For measurement of ALP activity, cells were
treated for 2 days without or with 50 μM genistein. The
ALP activity in the supernatant of cell homogenate was
measured using a kit for ALP (Alkaline phospha B-test;
Wako Pure Chemical Industries Ltd., Osaka, Japan)
according to the manufacturer’s instructions. The results
are expressed as the means ± SD of four plates.
Cell invasion and motility assays
Cell invasion and motility were determined using the
cell culture inserts with either matrigel-coated mem-
branes (6 wells, 8 μm pore size; BD Biosciences, Franklin
Lake, NJ) or uncoated membranes (12 wells, 8 μm pore
size; BD Biosciences) in the invasion chambers as
described previously [8]. Briefly, the chambers were
assembled using the inserts with either matrigel-coated
membranes or uncoated membranes and DMEM con-
taining 10% FBS as a chemoattractant in the lower com-
partment. LM8 cells, which had been treated without or
with 50 μM genistein for 3 days, were harvested by tryp-
sinization, and suspended in DMEM containing 0.1%
bovine serum albumin (BSA). The cells (5 × 105 cells/2
ml for invasion assay or 2.5 × 105 cells/ml for motility
assay) were added to the inserts. The assembled cham-
bers were incubated for 48 h or 24 h at 37°C. After re-
moval of non-migrating cells on the upper surface of the
membrane by wiping with a cotton swab, the cells on
the bottom surface of the membrane were fixed with
100% ethanol for 30 sec and stained with toluidine blue
for 10 min. The membrane was washed with ethanol
and dried. The dye was dissolved with 10% acetic acid
and quantitated by measuring the absorbance at 590 nm.
The results are expressed as the means ± SD for six
membranes.
Immunofluorescence and immunohistochemical staining
LM8 cells (1.19 × 103 cells/cm2) were incubated for 24 h
on a 2-well chamber slide (Nalge Nunc International,
Osaka, Japan). Then, cells were treated for 3 days with-
out or with 50 μM genistein. The cells were incubated
with 30 μM BrdU (Wako Pure Chemical Industries) dur-
ing the last 90 min of the 3-day treatment period, fixed
in 70% ethanol for 30 min, incubated in 100% ethanol
for 10 min, treated with 1.5 N HCl for 30 min, and
blocked with 0.5% Tween 20 for 5 min. Thereafter, cells
were incubated for 1 h with a mouse monoclonal anti-
BrdU antibody (1:15 dilution; Dako Japan, Inc., Tokyo,
Japan) followed by 1-h incubation with a fluorescein iso-
thiocyanate (FITC)-labeled anti-mouse IgG (1:20 dilu-
tion; Zymed Laboratories, Inc., San Francisco, CA) in
the dark. Cells were then mounted in fluorescence
mounting medium (Dako Japan) for fluorescent
Table 1 Primers used for RT-PCR analysis
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http://www.biomedcentral.com/1471-2121/13/24microscopy analysis (magnification: × 100). Five fields of
the culture were randomly photographed. The BrdU-
labeling index was calculated by dividing the number of
BrdU-positive cells by the total number of cells (170–795
cells/a field). The results are expressed as the mean ± SD
for five determinations. The antibodies used for immuno-
fluorescence and immunohistochemical staining were
diluted with PBS containing 1% BSA.
For immunofluorescence staining of β-catenin, cells
were treated for 3 days without or with 50 μM genistein,
fixed with ethanol as described above, and incubated for
1 h with a rabbit polyclonal antibody to β-catenin (1:15 di-
lution; Santa Cruz Biotechnology, Inc., Santa Cruz, CA)
followed by 1-h incubation with an FITC-labeled anti-
rabbit IgG (1:20 dilution; Santa Cruz Biotechnology) in
the dark. Cells were then mounted in fluorescence mount-
ing medium for fluorescent microscopy analysis (magnifi-
cation: × 400). For immunohistochemical staining of
MMP-2 and Drg-1, the ethanol-fixed cells were incubated
for 1 h with rabbit polyclonal antibodies to either MMP-2
or Drg-1 (1:15 dilution; Santa Cruz Biotechnology) fol-
lowed by 1-h incubation with horseradish peroxidase
(HRP)-conjugated ENVISION+ (Dako Japan). The posi-
tive cells were visualized by adding diaminobenthidine
(DAB; Dako Japan). The nuclei were counterstained with
hematoxylin. Cells were then mounted in glycergel (Dako
Japan) for light microscopy analysis (magnification: ×
400).
H&E staining
LM8 cells were treated for 3 days without or with 50 μM
genistein, fixed with ethanol as described above, and
stained with H&E. Cells were then mounted in glycergel
for light microscopy analysis (magnification: × 200). Five
fields of the culture were randomly photographed. The
ratio of the number of spindle-shaped cells to the total
number of cells (102–156 cells/a field) was estimated, with
the exception of multilayered cells. The results are
expressed as the mean ± SD for five determinations.
Western blot analysis
LM8 cells (1.25 × 103 cells/cm2) were incubated for 24 h
on a 60 mm plate. Then, cells were treated for 3 days
without or with 50 μM genistein, harvested in 0.6 ml of
solution A containing a protease inhibitor cocktail (1:100
dilution; Calbiochem-Novabiochem Co., La Jalla, CA),
sonicated briefly at 0°C, and centrifuged. The same
amount of supernatant protein (16.5 μg/lane) was sepa-
rated by sodium dodecyl sulphate-polyacrylamide gel elec-
trophoresis (SDS-PAGE, 7.5% acrylamide gel) and
transferred onto a PVDF membrane (GE Healthcare UK
Ltd. Buckinghamshire HP7 9NA, England). The mem-
brane was incubated for 1 h with rabbit polyclonal anti-
bodies to either β-catenin or actin (1:2,000 dilution; SantaCruz Biotechnology) followed by 1-h incubation with a
HRP-conjugated anti-rabbit IgG (1:25,000 dilution; GE
Healthcare). Blots were visualized using the ECL Advance
Western Blotting Detection Kit (GE Healthcare) according
to the manufacturer’s instructions. The experiment was
performed using four independent samples for each
treatment.
Assay of MMP-2 by gelatin zymography
LM8 cells were treated for 2 days without or with
50 μM genistein, washed 3 times with PBS, and incu-
bated with FBS-free DMEM for 1 h. The medium was
then replaced with FBS-free DMEM without or with
50 μM genistein, and the cells were incubated for 24 h.
The conditioned media were filtered through 0.2 μm fil-
ters. The activity of MMP-2 in conditioned media was
assayed by gelatin zymography as described previously
[8]. The experiment was performed using four independ-
ent samples for each treatment.
Total RNA isolation and RT-PCR
Total RNA was isolated from a 60 mm plate using a
GenElute Mammalian Total RNA Kit (Sigma-Aldrich)
according to the manufacturer’s instructions. Total RNA
(1 μg) was treated with DNase I (Sigma-Aldrich) and
then reverse-transcribed using the Transcriptor First
Strand cDNA Synthesis Kit (Roche, Indianapolis, IN)
according to the manufacturer’s instructions. 1 μl of
cDNA was subjected to PCR in a final volume of 25 μl
containing 1 × PrimeSTAR™ reaction buffer, 0.2 mM
dNTPs, 1 mM MgCl2, 0.4 μM of each primer, and
0.625 U of PrimeSTAR™ HS DNA Polymerase (Takara
Bio Inc., Otsu, Japan). The primers for mouse osteocal-
cin [38], mouse Drg-1 (from NCBI/Primer-BLAST), and
mouse β-actin [39] are listed in Table 1. The PCR condi-
tion was as follows: 10 sec at 98°C (denaturation), 10 sec
at 56°C (annealing), and 30 sec at 72°C (extension) for
osteocalcin and β-actin; 10 sec at 98°C, 10 sec at 60°C,
and 30 sec at 72°C for Drg-1. The PCR products were
separated on 2% agarose gels and visualized by ethidium
Nakamura et al. BMC Cell Biology 2012, 13:24 Page 9 of 10
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three independent RNA samples for each treatment.
Statistical analyses
Significant differences among multiple independent
groups were statistically evaluated using one-way ANOVA
and subsequent comparisons were made with the Tukey-
Kramer test. Significant differences between 2 independ-
ent groups were analyzed with Student’s t-test. For all
statistical analyses, the criterion for significance was
p < 0.05.
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